A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
Authors
McNamara, Mairéad GLe, L
Horgan, A
Aspinall, A
Burak, K
Dhani, N
Chen, E
Sinaei, M
Lo, G
Kim, T
Rogalla, P
Bathe, O
Knox, J
Affiliation
Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; The Christie NHS Foundation TrustIssue Date
2015-01-06
Metadata
Show full item recordAbstract
Second-line treatment options in advanced hepatocellular carcinoma (HCC) are limited. Axitinib, a selective potent tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor VEGF) receptors 1, 2, and 3, merits exploration in HCC.Citation
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. 2015: CancerJournal
CancerDOI
10.1002/cncr.29227PubMed ID
25565269Type
ArticleLanguage
enISSN
1097-0142ae974a485f413a2113503eed53cd6c53
10.1002/cncr.29227